ClinicalTrials.gg

Program

WRN Inhibitor RO7589831

Its studies are mostly in Colorectal Neoplasms, Hereditary Nonpolyposis · Colorectal Neoplasms, led by Bayer.

Furthest: phase 2, since Sep 2, 20262 company-led studies, 2 open or runningNext primary completion: May 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bayer22 open or runningphase 2since Sep 2, 2026Aug 16, 2023May 31, 2027phase 1 · NCT06004245

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 16, 2023First study: phase 1 study in Colorectal NeoplasmsFirst studyNCT06004245 · 280 planned · United States, Australia, Belgium and more
  2. Sep 2, 2026Phase 2 study in Colorectal Neoplasms, Hereditary NonpolyposisPhase 2 reachedNCT07811193 · 140 planned · United States, Argentina, Belgium and more

Ahead

  1. May 31, 2027Primary completion: phase 1 study in Colorectal NeoplasmsNCT06004245
  2. Jun 30, 2028Primary completion: phase 2 study in Colorectal Neoplasms, Hereditary NonpolyposisNCT07811193

TargetBeta

WRN →read by rule
“An orally bioavailable and small molecule inhibitor of Werner syndrome ATP-dependent helicase (WRN; RecQ protein-like 2; Werner syndrome protein), ”NCIt, by rule

Other programs on WRN

ProgramCompanyFurthest phaseStudies
WRN Inhibitor GSK4418959ruleGlaxoSmithKlinephase 21
WRN Inhibitor NDI-219216rulenimbus-wadjet-incphase 21
WRN Inhibitor EIK1005ruleeikon-therapeuticsphase 21
WRN Inhibitor MOMA-341rulemoma-therapeuticsphase 11
WRN Inhibitor AMG 436ruleAmgenphase 11

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07811193Colorectal Neoplasms, Hereditary Nonpolyposis · United States, Argentina, Belgium and more2RecruitingJun 30, 2028140
NCT06004245Colorectal Neoplasms · United States, Australia, Belgium and more1RecruitingMay 31, 2027280

How it is read

Names in the registry

  • “VVD-133214”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.